<div id="readability-page-1"><p><span>Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report)</span> was upgraded by equities researchers at TD Cowen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note issued to investors on Monday. The brokerage currently has a $8.00 target price on the stock. TD Cowen's price target suggests a potential upside of 239.70% from the stock's previous close.</p><p>MIST has been the subject of several other reports. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Milestone Pharmaceuticals in a report on Monday, December 1st. Wells Fargo &amp; Company initiated coverage on Milestone Pharmaceuticals in a research note on Thursday, September 11th. They issued an &#34;overweight&#34; rating and a $4.00 price target on the stock. Finally, Wall Street Zen lowered shares of Milestone Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Three analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company  has a consensus rating of &#34;Hold&#34; and a consensus price target of $5.67.</p><p><b>Check Out Our Latest Stock Report on MIST</b></p><h2>Milestone Pharmaceuticals Trading Down 2.3%</h2><p>MIST stock traded down $0.06 on Monday, reaching $2.36. The company's stock had a trading volume of 42,738,590 shares, compared to its average volume of 2,079,424. The firm has a market cap of $200.58 million, a PE ratio of -2.79 and a beta of 0.40. The business has a fifty day simple moving average of $2.18 and a two-hundred day simple moving average of $1.91. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. </p><p>Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05.  As a group, research analysts forecast that  Milestone Pharmaceuticals will post -0.62 EPS for the current year. </p><h2>Institutional Investors Weigh In On Milestone Pharmaceuticals</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of MIST. Propel Bio Management LLC lifted its position in  Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company's stock valued at $10,250,000 after purchasing an additional 3,333,333 shares in the last quarter.  Orbimed Advisors LLC bought a new position in shares of  Milestone Pharmaceuticals during the 3rd quarter valued at approximately $6,444,000.  Simplify Asset Management Inc. increased its holdings in  Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company's stock worth $5,666,000 after acquiring an additional 1,842,974 shares in the last quarter.  Pathstone Holdings LLC bought a new stake in  Milestone Pharmaceuticals during the 3rd quarter worth approximately $2,000,000.  Finally, Boxer Capital Management LLC purchased a new position in  Milestone Pharmaceuticals during the third quarter valued at approximately $1,333,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Milestone Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Milestone Pharmaceuticals</li><li>Russell 2000 Index, How Investors Use it For Profitable Trading</li><li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li><li>What Are Dividend Achievers? An Introduction</li><li>GOOGL's Unstoppable Momentum Drives Price Targets to Record Highs</li><li>3 Warren Buffett Stocks to Buy Now</li><li>3 Underrated Robotics Stocks Poised for Huge Gains</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlTVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Milestone Pharmaceuticals Right Now?</h2><p>Before you consider Milestone Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.</p><p>While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MIST

<p>TD Cowen upgraded Milestone Pharmaceuticals (NASDAQ:MIST) from "hold" to "buy," setting a $8.00 price target, suggesting a 239.70% upside. Despite mixed ratings from other analysts, the stock has a consensus "hold" rating with a $5.67 target. Institutional investors have increased their holdings significantly. Milestone focuses on cardiovascular medicines, with its lead product etripamil in clinical trials. The stock traded down 2.3% to $2.36, with a market cap of $200.58 million.</p>

Milestone Pharmaceuticals (NASDAQ:MIST) Raised to Buy at TD Cowen